Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • ObservationalRecruiting Location: Australia - NSW, QLD, SA, WA, VIC

    BEAT CF platform: A digital infrastructure and data collection tool to evaluate treatments for pulmonary exacerbations in children and adults with Cystic Fibrosis. , protocol number ACTRN12621000638831

    With every respiratory exacerbation of CF, approximately 25% of patients do not return to their baseline lung function. Preservation of lung function is important for extending life and for quality of life, thus there is a need to determine the most effective empirical treatments of exacerbations.

    • Age:

      No limit

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Australia - NSW, QLD, SA, WA, VIC

    BEAT CF: Pulmonary Exacerbations Treatment Platform - Backbone Antibiotics Domain , protocol number ACTRN12622000950763

    An evaluation of the comparative effectiveness of prescribing various standard of care, first-line Backbone Antibiotics in the management of pulmonary exacerbations requiring intensive therapy (PERIT) in children and adults with CF, with respect to their short-term improvement in lung function.

    • Age:

      Minimum Age 5 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Australia - NSW, QLD, SA, WA,VIC

    BEAT CF: Pulmonary Exacerbations Treatment Platform - Adjunct Antibiotics Domain , protocol number ACTRN12622001063707

    An evaluation of the comparative effectiveness of prescribing various standard of care, adjunct Antibiotics in the management of pulmonary exacerbations requiring intensive therapy (PERIT) in children and adults with CF, with respect to their short-term improvement in lung function.

    • Age:

      Minimum Age 5 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Multiple US Locations

    Study of ARV-1801 (ACG-701) for the treatment of pulmonary exacerbations in CF patients 12 years of age or older. (Aceragen ARV-1801 ) , protocol number NCT05641298

    This study will evaluate the efficacy and safety of the study drug ARV-1801, an oral drug intended to treat infections in the lung. The study also will evaluate how the body processes the drug.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      28 Days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US Locations

    Study to evaluate VX-522 in adults 18 years and older with cystic fibrosis. (Vertex VX21-522-001 SAD) , protocol number NCT05668741

    This study will evaluate the safety and tolerability of VX-522, an investigational gene therapy, in adults with CF whose mutations are not responsive to CFTR modulator therapy.

    • Age:

      18 to 65 Years Old

    • Mutation(s):

      No Copies F508del

    • FEV1% Predicted:

      40% or greater

    • Number of Visits:

      8

    • Length of Participation:

      Six months

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Western Australia

    Immediate effects of the MetaNeb® compared to huff and cough in adults with stable cystic fibrosis , protocol number ACTRN12621000855820

    This project will look at the effects effect of a single 30-minute session using the MetaNeb® device versus a single session of directed huff and cough (control) on the primary outcome of lung structure, regional perfusion and ventilation and secondary outcomes of respiratory mechanics, airflow obstruction, sputum expectoration and symptoms related to CF in adults with stable CF. Our hypothesis is, in this population, a single MetaNeb® treatment, will be more effective in changing and/or improving these primary and secondary outcomes than huff and cough alone.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionRecruiting Location: NSW, Australia

    A Phase I Study of Inhaled KB407, a Replication-Incompetent, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), for the Treatment of Cystic Fibrosis , protocol number NCT05095246

    The study will evaluate the safety and tolerability of nebulised KB-407. KB-407 is a viral vector that uses the abilitv of HSV-1 (herpes simplex virus) to deliver functional CFTR to the airways of people with cystic fibrosis. The viral vector does not cause disease since it has been modified by removing the genes responsible for replication. This study will enrol 4 participants into the first cohort. They will receive a single dose of KB407 and be followed for 60 days.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      FEV1 =50% and =100%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple US locations

    Study of galicaftor/navocaftor/ABBV-576 combination therapy in adults with cystic fibrosis who have at least one F508del mutation and are on stable elexacaftor/tezacaftor/ivacaftor (Trikafta) treatment (Abbvie M19-771) , protocol number ABBV-576 NCT04853368

    This study will look at the safety and effectiveness of galicaftor/navocaftor/ABBV-576 combination therapy, a combination of CFTR modulators intended to help CFTR protein function closer to normal. This study is for adults with cystic fibrosis who have at least one F508del mutation.

    • Age:

      18 Years and Older

    • Mutation(s):

      Two Copies F508del or One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      6

    • Length of Participation:

      3 months

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Multiple care centres across the US

    Study to evaluate the standardizing of treatment for pulmonary exacerbations in children and adults with CF ages 6 and older. (STOP360-IP-22) , protocol number NCT05548283

    This study will look at pulmonary exacerbations, which are a worsening of respiratory symptoms, in people with CF who need to be treated with intravenous (IV) antibiotics. It will compare treatment with one antibiotic (a beta-lactam) to treatment with two antibiotics (tobramycin and a beta-lactam) to learn whether there is a difference in lung function and symptom improvement between the two groups. This study is for people ages 6 and older.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      82% or greater

    • Number of Visits:

      3

    • Length of Participation:

      48 days

    Contact us about this clinical Trial >
  • ObservationalRecruiting Location: Western Australia

    Family Surfing Activity for Children and adolescents with chronic conditions: Effects on Health and Well-being , protocol number ACTRN12622001168741

    This study aims to evaluate the effects of a family-based surfing intervention on the physical and psychological wellbeing of children and adolescents with chronic conditions.

    • Age:

      7-18 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Displaying results 1-10 (of 237)
     |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|